Organon & Co. Common Stock vs IAC/Interactivecorp — how do they compare? Organon & Co. Common Stock trades at $13.58 (market cap $3.62B), while IAC/Interactivecorp trades at $40.57 (market cap $3.04B). The key difference: Organon & Co. Common Stock is the larger of the two by market cap, and Organon & Co. Common Stock pays a 0.58% dividend while IAC/Interactivecorp pays none. Which is the better fit depends on your goals — on Pluang, investors hold Organon & Co. Common Stock for 0 Days and IAC/Interactivecorp for 80 Days on average.
| OGN | PPLI | |
|---|---|---|
Market Cap | $3.62B | $3.04B |
Volume | 2,892,999 | 686,384 |
Sector | Health | Media |
52-Week High | $13.81 | $47.62 |
52-Week Low | $5.70 | $31.52 |
Typical Hold Time | 0 Days | 80 Days |
Enterprise Value | $11.04B | $3.52B |
Dividend Yield | 0.58% | — |
Signals from Pluang's Aura AI — not financial advice
Organon (OGN) trades at $13.77, showing no change in the latest session. The stock demonstrates strong profitability with 52.68% gross margins and 24.04% ROE, though recent quarterly earnings have missed expectations. Valuation appears reasonable with P/E of 17.65 and P/S of 0.59. The company shows positive cash flow trends with 2026 projections indicating $533M net cash flow. Recent FDA developments for MIUDELLA and VTAMA products highlight ongoing pipeline progress.
OGN presents a mixed outlook with solid fundamentals offset by earnings misses. The healthcare company's improving cash flow and product pipeline offer potential upside, but investor sentiment remains divided with analysts showing cautious optimism. Key risks include execution challenges and competitive pressures in the pharmaceutical sector.
PPLI trades at $40.56, down 0.73% with mixed technical signals showing bullish moving averages but neutral oscillators. The company reported a net loss of $104.03M in 2025 despite strong gross margins of 66.35%, with valuation metrics appearing attractive at P/E of 6.91 and P/B of 0.6. Recent MGM acquisition speculation has driven significant volatility, with shares surging 11.3% on takeover rumors according to Zacks Investment Research on September 28, 2026.
The outlook remains speculative with 71% analyst buy ratings supporting potential upside from strategic developments, though fundamental weakness in recent earnings and negative cash flow trends present significant risks. Investors face binary outcomes dependent on MGM deal progression versus underlying business challenges in the media sector.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Organon & Co. is a global healthcare company focused on women's health, biosimilars, and established brands, spun off from Merck & Co. in 2021. Its portfolio of more than 70 medicines includes contraception and fertility therapies, immunology and oncology biosimilars, and treatments in cardiovascular, respiratory, and dermatology, distributed in over 140 countries.
Read more on OGN →IAC Inc is an Internet media company with segments that include Angi (47% of total revenue), Dotdash (10%), search (24%), and emerging and other (19%). The firm spun off the narrow-moat dating app provider Match Group in second-quarter 2020 and the no-moat video software provider Vimeo in second-quarter 2021.
Read more on PPLI →